Stem cell research is still too hot for most investors, but NeoStem is starting to change that, thanks to some unexpected events. Among them are the Catholic Church’s surprising embrace of NeoStem’s research and NeoStem’s footh…
Among the day’s top stories for investors: Does your family need tech detox? Why Dendreon keeps going up? And, what do 50 Cent, Carmen Electra, and Shaq have in common?
Continue reading Daily Blogwatch: Choosin…
Much like Dendreon, which has a promising prostate cancer drug, ImmunoCellular is developing a cancer drug. In this case, it battles brain cancer, and a Phase I trial turned in remarkable results. But unlike Dendreon, ImmunoCel…
Dendreon’s Provenge, which targets prostate cancer, catapulted that company’s stock to record highs recently. Prima Biomed’s CVac works similarly, but it has the potential to target multiple forms of cancer, giving the company …